再鼎醫藥(09688.HK)SUL-DUR新藥上市申請獲納入優先審評
再鼎醫藥(09688.HK)(ZLAB.US)公布,目前正在開發的注射用舒巴坦鈉-注射用度洛巴坦鈉組合包裝(SUL-DUR),用於治療鮑曼不動桿菌(包括多重耐藥和耐碳青黴烯類菌株)感染的新藥上市申請,已於近日獲國家藥監局藥品審評中心納入優先審評。
再鼎醫藥總裁,中樞神經系統、自身免疫及感染性疾病領域全球開發負責人任海睿表示,多重耐藥和耐碳青黴烯類是最為嚴重的細菌感染之一,藥品審評中心將SUL-DUR獲納入優先審評,反映出此類患者對於該創新治療手段的迫切需要。
SUL-DUR是由Entasis Therapeutics開發的一款處於研究階段的、靜脈輸注型新藥,再鼎醫藥擁有在大中華區、南韓、越南、泰國、柬埔寨、老撾、馬來西亞、印尼、菲律賓、新加坡、澳洲、新西蘭和日本的開發及商業化獨家授權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.